Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and efficacy of sequential infusion of CD19‐CART and B‐cell...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Med
Päätekijät: Yan, Lingzhi, Qu, Su, Shang, Jingjing, Shi, Xiaolan, Kang, Liqing, Xu, Nan, Zhu, Mingqing, Zhou, Jin, Jin, Song, Yao, Weiqin, Yao, Ying, Chen, Guanghua, Chang, Huirong, Zhu, Xiaming, Yu, Lei, Wu, Depei, Fu, Chengcheng
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7877347/
https://ncbi.nlm.nih.gov/pubmed/33356013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3624
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia